G6PD and malaria: Several, more recent clinical trials of dapsone-containing drug regimens for the treatment of malaria have confirmed a significant rate of hemolytic anemia in G6PD-deficient individuals receiving dapsone-containing treatments, with many patients having significant hemolytic reactions requiring blood transfusions [16-18].